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Abstract Prostaglandin E2 receptors (EPR) belong to the 
family of G-protein-coupled receptors with 7 transmembrane 
domains. They form a family of four subtypes, which are linked 
to different G-proteins. EPiR are coupled to Gq, EP2 and EP4R 
to Gs and EP3R to G;. Different C-terminal splice variants of the 
bovine EP3R are coupled to different G-proteins. A mouse EP3R 
whose C-terminal domain had been partially truncated no longer 
showed agonist-induced Gj -protein activation and was constitu-
tively active. In order to test the hypothesis that the C-terminal 
domain confers coupling specificity of the receptors on the 
respective G-proteins, a cDNA for a hybrid rEP3hEP4R, 
containing the N-terminal main portion of the Gj-coupled rat 
EP3ßR including the 7th transmembrane domain and the 
intracellular C-terminal domain of the Gs-coupled human 
EP4R, was generated by PCR. HEK293 cells transiently 
transfected with the chimeric rEP3hEP4R cDNA expressed a 
plasma membrane PGE2 binding site with a slightly lower Kd 
value for PGE2 but an identical binding profile for receptor-
specific ligands as cells transfected with the native rat EP3ßR. In 
HepG2 cells stably transfected with the chimeric rEP3hEP4R 
cDNA PGE2 did not increase cAMP formation characteristic of 
Gs coupling but attenuated the forskolin-stimulated cAMP 
synthesis characteristic of Gj coupling. This effect was inhibited 
by pre-treatment of the cells with pertussis toxin. Thus, the 
hybrid receptor behaved both in binding and in functional 
coupling characteristics as the native rat EP3ßR. Apparently, the 
intracellular C-terminal domain did not confer coupling specific-
ity but coupling control, i.e. allowed a signalling state of the 
receptor only with agonist binding. 
Key words: Prostaglandin receptor; Chimeric receptor; G-
protein coupling 
1. Introduction 
Prostaglandin E2 (PGE2) is a potent mediator of physiolog-
ical and pathophysiological events in the body, for example 
stimulation of neurotransmitter release, regulation of the im-
mune system and uterus contraction [1-3]. Its actions are 
mediated by binding to specific PGE2 ectoreceptors (EPR), 
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which belong to the family of G-protein-coupled receptors 
with 7 transmembrane domains. According to their affinity 
to receptor-specific agonists and antagonists and to the intra-
cellular signal chains to which they are coupled, these recep-
tors can be divided into 4 subclasses [4]: E P ^ are coupled to 
Gq, EP2R and EP4R to Gs and EP3R receptors to G;. Binding 
of PGE2 to EP3R on rat hepatocytes decreased glucagon-stim-
ulated cAMP formation and glucose output [5] while binding 
of PGE2 to EP4R on human T-lymphocytes increased cAMP 
formation involved in differentiation and proliferation proc-
esses [6]. 
The PGE2 receptors of the different subclasses display an 
overall homology of < 50% with the transmembrane regions 
being most conserved. However, the C-terminal domains of 
the Gj-coupled rat EP3ßR (rEP3ßR), which consists of 36 ami-
no acids, and the Gs-coupled human EP4R (hEP4R), which 
consists of 156 amino acids, have no homology [7,8]. 
The observation that different C-terminal splice variants of 
the bovine EP3R were coupled to different G-proteins [9] led 
to the hypothesis that the C-terminal domain of the EPR 
might play an important role in G-protein coupling specificity. 
In order to test this hypothesis a cDNA for a receptor hybrid 
rEP3hEP4R containing the N-terminal region of the rEP3ßR 
including the 7th transmembrane domain and the C-terminal 
domain of the hEP4R was generated by PCR. After expres-
sion of the hybrid receptor by transient or stable transfection 
ligand binding and cAMP formation were measured to ana-
lyze binding behavior and the signal chain to which the hybrid 
receptor was coupled in comparison to the two parental re-
ceptors. The hybrid receptor behaved like the native rEP3ßR 
indicating that the C-terminal domain did not confer G-pro-
tein coupling specificity. 
2. Materials and methods 
2.1. Materials 
All materials were of analytical grade and from commercial sources. 
M&B 28767 and AH 23848B were generous gifts from Rhone-Poulenc 
Rorer (Dagenham, UK) and Glaxo (Hertfordshire, UK), respectively. 
[3H]PGE2 was obtained from Amersham (Braunschweig, Germany), 
unlabeled prostaglandins were purchased from Serva (Heidelberg, 
Germany) or Cascade (Berkshire, UK). Geneticin (G-418 sulfate) 
and cell culture media were obtained from Gibco-BRL (Eggenstein, 
Germany), forskolin was from ICN (Meckenheim, Germany) and 
pertussis toxin from Calbiochem-Novabiochem (Bad Soden, Ger-
many). Primers (Table 1) were synthesized by Pharmacia (Freiburg, 
Germany). The sources of other materials are given in the text. 
2.2. Cloning of rat EP3p and human EP^ receptor cDNAs 
Cloning of the rEP3pR cDNA was carried out as described [7]. For 
cloning of the I1EP4R total RNA was isolated from human T-lym-
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phocytes by CsCl gradient centrifugation [10]. Poly(A)+ mRNA was 
prepared by affinity purification using oligo-(dT) beads from Qiagen 
(Rathingen, Germany) according to the manufacturer's instructions. 
First strand cDNA was synthesized by oligo-(dT)i2-i8-primed reverse 
transcription. PCR was carried out using 10 ng first strand cDNA as a 
template and oligonucleotide primers PI and P2 (Table 1) correspond-
ing to positions 261-287 and 1905-1879 of the hEP4 receptor [6]. 
Thirty-five cycles of PCR using proof-reading Pwo polymerase were 
performed with the following temperature profile: 1 min 95°C, 1 min 
60°C and 3 min 72°C. A 1643 bp fragment was amplified and cloned 
blunt end into the Smal site of pBluescript (Stratagene, La Jolla, CA, 
USA). The insert was sequenced in both directions by cycle sequen-
cing with dye-dideoxy terminator NTPs on the automatic DNA se-
quencer 373A (Applied Biosystems, Weiterstadt, Germany). 
2.3. Construction of the chimeric rEP^hEP^ receptor cDNA 
The cDNA for the chimeric rEP3hEP4R was constructed by recom-
binant PCR technology [11]. Using the cDNAs of the rEP3ßR and the 
hEP4R cloned into PUC 18 as templates, the N-terminal portion of 
the rEP3ßR up to the end of the 7th transmembrane domain and the 
C-terminal domain of the I1EP4R were amplified by PCR in separate 
reactions using primer pairs P3/P5 for the rEP3pR and P4/P6 for the 
hEP4R (Table 1). Primers P4 and P5 hybridized with their 3'-part to 
the respective template and were complementary to the other cDNA 
with their overhanging 5'-part. The 1161 bp (N-terminal rEP3pR frag-
ment and 521 bp (C-terminal hEP4R fragment) PCR products were 
isolated, mixed and fused in a third PCR using the primer pair P3/P6. 
All PCRs were performed with 10 ng template and 35 cycles of the 
following temperature profile: 1 min 95°C, 1 min 55°C and 2 min 
72°C. The resultant 1660 bp cDNA fragment was cloned into 
PUC 18 and verified by DNA sequencing. 
2.4. Transient expression of receptor cDNAs 
The cDNAs for rEP3pR and the chimeric rEP3hEP4R were sub-
cloned into the Notl site of the eukaryotic expression vector pcDNA 
I (Invitrogen, San Diego, CA, USA). The resultant plasmids were 
transfected into HEK293 cells by a calcium phosphate method using 
5% (v/v) modified bovine serum from Stratagene. The EcoRIIBamHI 
fragment of the hEP4R was subcloned into pcDNA/AMP (Invitrogen) 
and the resultant plasmid was transfected into COS-7 cells or HepG2 
cells using the DEAE-dextran method including chloroquine [12]. 
Transfected cells were cultured for 72 h in DMEM with 10% FCS 
for HEK293 and COS-7 cells, or MEM with 10% FCS for HepG2 
cells. For membrane preparations, the cells were scraped into a ho-
mogenization buffer containing 25 mM Tris-HCl pH 7.5, 250 mM 
sucrose, 10 mM MgCl2, 1 mM EDTA and 1 mM phenylmethylsul-
fonyl fluoride. After homogenization of the cells in a Dounce homog-
enizer a crude membrane fraction was prepared by centrifugation of 
the homogenate at 100000Xg. The resulting pellet was suspended in 
binding buffer containing 25 mM MES/NaOH pH 6.2, 10 mM MgCl2 
and 1 mM EDTA and stored at -20°C. 
2.5. PGE2 binding assays with membranes of transfected HEK293 or 
COS-7 cells 
For ligand binding membranes (20-50 μg protein) were incubated 
with 5 nM [3H]PGE2 and various concentrations of unlabelled PGE2, 
the EP3R agonist M&B 28767 and the EP4R antagonist AH23848B in 
100 μΐ binding buffer for 1 h at 20°C. Non-specific binding was de-
termined in the presence of 10 μΜ PGE2. Bound and unbound ligand 
were separated by rapid vacuum filtration through GF 52 filters 
(Schleicher & Schuell, Dassel, Germany). Filters were washed 5 times 
with 4 ml ice-cold binding buffer. Radioactivity retained on the filter 
was counted in 5 ml Hydroluma (Baker, Deventer, The Netherlands). 
Binding constants were calculated by non-linear regression analysis 
(LIGAND [13]). 
2.6. Stable expression of rat EP3p receptor in CHO and rEP^hEPt, 
receptor in HepG2 cells 
Stable expression of the rEP3pR in CHO cells was carried out as 
described previously [7]. The 1.66 kb Notl cDNA fragment for the 
rEP3hEP4R was subcloned into the eukaryotic expression vector pRc/ 
CMV (Invitrogen). 20 μg of the resultant plasmid was linearized and 
transfected into 107 HepG2 cells by a calcium phosphate method 
using 5% (v/v) MBS. Transfectants were isolated in MEM containing 
10% (v/v) FCS and 0.5 mg/ml G-418 as substrate of the selection 
marker aminoglycoside phosphotransferase (NEO). Clonal cell lines 
were isolated by single cell cloning and tested for expression by PGE2 
binding. 
2.7. cAMP formation in transfected CHO or HepG-χ cells 
CHO cells stably expressing the rEP3ßR and HepG2 cells stably 
expressing the chimeric rEP3hEP4R were cultured in 3.5 cm diameter 
plates to a density of 5 X 105 in HAM-F12 medium containing 10% (v/ 
v) FCS for CHO cells and 1.2 mg/ml G-418 or MEM containing 10% 
FCS and 0.5 mg/ml G-418 for HepG2 cells. cAMP assays with HepG2 
cells transiently transfected with the I1EP4R were performed 72 h after 
transfection. Where indicated, cells were pretreated with PTX (100 ng/ 
ml) for 16 h. Cells were washed 3 times with 1 ml HEPES buffer pH 
7.4 containing 140 mM NaCl, 4.7 mM KC1, 2.2 mM CaCl2, 1.2 mM 
KH2PO4, 11 mM glucose and 15 mM HEPES and then pre-incubated 
in 1 ml of the same buffer with 1 mM IBMX at 37°C for 10 min. Then 
PGE2, M&B 28767, AH23848B and forskolin (100 μΜ) were added in 
a volume of 10 μΐ buffer to the final concentration indicated. After 
incubation for 10 min the reaction was stopped by removing the 
buffer and freezing the cells in liquid nitrogen. Cells were lysed in 
500 μΐ 10 mM HC1 containing 1 mM IBMX for 1 h at 4°C. The 
lysate was centrifuged and cAMP was quantified in the supernatant 
with a 125I-cAMP assay kit of Amersham (Braunschweig, Germany). 
3. Results and discussion 
3.1. Construction of the cDNA for the chimeric rEP^hEP^R 
A c D N A for a chimeric receptor consisting of the N-termi-
nal main port ion of the Gj-coupled rEP3pR including the 7th 
t ransmembrane domain and the C-terminal intracellular do-
main of the G s-coupled h E P 4 R (cf. Fig. 1) was constructed by 
recombinant P C R technology. The junction between the 7th 
t ransmembrane domain and the C-terminal domain is marked 
both in the rEP3ßR and the hEP4R by an arginine/lysine (R/ 
K) pair and these two amino acids are conserved in most 
prostaglandin receptors [14]. The C-terminal domains of the 
two receptors are different in size (Fig. 1). The I1EP4R C-
terminal domain is 4.5-fold larger and contains no partial 
sequence with significant homology to the C-terminal domain 
of the rEP3pR. The chimeric rEP 3 hEP 4 R c D N A was cloned 
into P U C 18 and sequenced. The two receptor parts were fused 
in the correct position maintaining the original reading frame. 
Table 1 
Primers used to amplify receptor cDNAs 
Sequence Receptor and position 
PI 5'-AAAGCAGGTTGGAGGCGGGTCCAG-3' 
P2 5'-CAGGATTTTATAAGGGTCCAGAAACAG-3' 
P3 5'-AGCGACCGGCGCTCAGCTGG-3' 
P4 5'-GGATCCCTGGGTTTATCTGCTGCTA/ 
AGAAAGACAGTGCTCAGTAAAGC4-3 
P5 inverted complementary sequence of P4 
P6 5'-tcgcggccgctCAGGATTTTATAAGGGTCCAGAAACAG-3' 
hEP4R (Genbank accession number: L28175) pos. 261-287 (forward) 
hEP4R, pos. 1905-1879 (reverse) 
sequence flanking the EcoKl site of the vector Xgtl 1 (short arm), 
originally used to amplify the rEP3pR cDNA cloned in Xgtl 1 [7] 
(forward) 
rEP3pR (Genbank accession number: X80133), pos. 1056-1080/hEP4R, 
pos. 1385-1408 (forward) 
(reverse) 
Primer P2+recognition site for Notl at the 5'-end (lower case) (reverse) 
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cific ligand in competition binding studies because it bound to 
rEP3pR, the hybrid rEP3hEP4R and hEP4R with similar low 
affinity (Fig. 2). This is in line with the finding that AH23848B 
besides being a weak EP4R antagonist is also a weak agonist 
at EP3R [16]. 
The I1EP4R C-terminal domain in the hybrid rEP3hEP4R 
thus did not shift the ligand binding characteristics towards 
the I1EP4R profile. The binding behavior of the hybrid 
rEP3hEP4 receptor was similar to the rEP3ß receptor except 
that the apparent Kd for PGE2 binding was about 5-fold low-
er in the chimeric receptor. This could be a reaction of small 
conformational changes in the receptor caused by the intro-
duced foreign C-terminal domain which was in direct contact 
to the 7th transmembrane domain. The 7th transmembrane 
domain was postulated to be involved in forming the ligand 
binding site [14]. A change in receptor binding affinity which 
was caused by intracellular sequence mutations could be 
shown for the Ml muscarinic receptor, where mutations in 
the second intracellular loop led to a higher ligand affinity 
in mutant receptors [17]. 
Fig. 1. Hypothetical structure of the G;-coupled rat PGE2 receptor 
(rEP3ßR), the Gs-coupled human PGE2 receptor (hEP4R) and a chi-
meric rEP3hEP4 receptor (rEP3hEP4R). Glycosylation sites in the 
N-terminal domains and the second extracellular loops as well as 
potential phosphorylation sites for PKA, PKC and ß-adrenergic re-
ceptor kinases (ßARKs) in the intracellular loops and the C-termi-
nal domains have been omitted for clarity. SS: location of the splice 
site in the EP3R. 
The sequences of the respective receptor parts were 100% 
identical to the parental receptors domains. 
3.2. Binding characteristics of the chimeric rEP^hEPi receptor 
Parental receptors and the rEP3hEP4R hybrid were ex-
pressed transiently in order to compare the binding character-
istics of the receptors. While the rEP3ßR and the rEP3hEP4R 
were expressed efficiently in HEK293 cells, high level expres-
sion of the hEP4R was achieved in COS-7 cells only. The 
receptors were expressed to yield a similar maximal binding 
in the respective membrane preparations. 
Membranes of cells transfected with either of these recep-
tors displayed a single binding site for PGE2. Apparent Kd 
values were 15 nM for the rEP3ßR, 3 nM for the rEP3hEP4R 
hybrid and 3 nM for the hEP4R (Fig. 2). Thus, the Kd value 
of the hybrid receptor was 5-fold lower than the Kd value of 
the parental rEP3ßR and identical to the Kd value of the 
hEP4R. However, a Kd value of 3 nM has been reported for 
the mouse EP3ßR that has 97% homology to the rEP3pR and 
89% homology in the C-terminal domain [15]. 
rEP3ßR and hEP4R bound PGE2 with similar affinity but 
hEP4R had an almost 100-fold lower affinity for the EP3R-
specific ligand M&B 28767. The rEP3hEP4R hybrid bound 
M&B 28767 with the same Kd as the rEP3ßR (Fig. 2). 
AH23848B has been reported to be a specific antagonist of 
EP4R, however, it proved not to be useful as a receptor-spe-
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Fig. 2. Competition by PGE2, M&B 28767 and AH23848B of 
[3H]PGE2 binding to membranes of HEK293 cells transfected with 
pcDNA I/rEP3pR, pcDNA I/rEP3hEP4R or of COS-7 cells trans-
fected with pcDNA I/AMP/hEP4R. Cells were transfected as de-
scribed in Section 2. Binding of 5 nM [3H]PGE2 to membranes of 
transfected cells was measured after 1 h at 20°C in the presence of 
the indicated concentrations of unlabelled PGE2 or its analogs. 
M&B 28767 is an EP3R agonists and AH23848B is an EP4R an-
tagonist. [3H]PGE2 binding in the presence of 10 μΜ PGE2 was de-
fined as unspecific binding. Maximal specific binding was set equal 
to 100%. Values are means ±S.E. of 3 different experiments per-
formed in duplicate. 
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mation by only 60%. In HepG2 cells which were transiently 
transfected with the cDNA for the hEP4R 1 μΜ PGE2 in-
creased cAMP levels by 9-fold (Fig. 3c). This PGE2-mediated 
cAMP increase was not affected by PTX pretreatment. Thus, 
the hEP4R was exclusively coupled to a Gs and not to Gi 
protein. (Fig. 3c). 
In dose-response curves with HepG2/rEP3hEP4R cells 
PGE2 and the EP3R agonist M&B 28767 inhibited forsko-
lin-stimulated cAMP formation half-maximally with an ap-
parent IC5o of about 1 nM which was in the same concentra-
tion range as needed for 50% competition of [3H]PGE2 
binding (Fig. 4). M&B 28767 inhibited forskolin-stimulated 
cAMP formation with a similar IC50 as in CHO/rEP3ßR cells 
but a 10-fold lower PGE2 concentration was needed for half-
maximal inhibition, which is in line with the lower Aj for 
PGE2 observed in the binding studies with the rEP3hEP4R 
(Fig. 2b). These data show that the functional properties of 
the chimeric rEP3hEP4R were similar to those of the G;-
coupled rEP3ßR and that the C-terminal domain of the 
hEP4R led to a slightly higher affinity for PGE2 in the chi-
meric rEP3hEP4R. 
Fig. 3. Modulation of cAMP formation in CHO/rEP^R, 
HepG2/rEP3hEP4R and HepG2/hEP4R cells by PGE2. CHO cells 
were stably transfected with the pRc/CMV/rEP3|jR construct. 
HepG2 cells were stably transfected with the pRc/CMV/rEP3hEP4R 
construct or transiently transfected with the pcDNA I/AMP/hEP4R 
construct. cAMP formation induced by 1 μΜ forskolin, 1 μΜ 
PGE2 or 1 μΜ forskolin+1 μΜ PGE2 after 10 min at 37°C was de-
termined by radioimmunoassay. cAMP formation in forskolin-stim-
ulated (a, b) or unstimulated cells (c) was set equal to 100%. Values 
are means ± S.E. of 3 different experiments performed in duplicate. 
Statistics: Student's /-test for unpaired samples: a, i><0.01; n.s., 
not significant. 
3.3. Functional properties of the stably expressed rEP^hEPi 
receptor 
To analyze the intracellular signal chain of the chimeric 
receptor, the rEP3hEP4R cDNA was cloned into pRc/CMV 
and stably expressed in HepG2 cells. HepG2 cells were used 
because they lack intrinsic EP3R, EP2R or EP4R. In contrast 
HEK293, COS-7 and CHO cells possess EP2R and/or EP4R 
and, as a consequence, showed a strong (HEK 293 and COS-7 
cells) or slight (CHO cells) increase in cAMP formation upon 
PGE2 stimulation in the untransfected state (data not shown). 
A clonal cell line, HepG2/rEP3hEP4R, expressing a PGE2 
binding site was isolated. In these cells 1 μΜ PGE2 inhibited 
the forskolin-induced cAMP formation by 80% (Fig. 3b). The 
PGE2-mediated inhibition of the forskolin-stimulated cAMP 
production was suppressed by only 10%, if the cells were 
pretreated with PTX. PGE2 did not increase cAMP formation 
in either control or PTX-treated HepG2/rEP3hEP4R cells. 
Thus, the rEP3hEP4R hybrid coupled to a PTX-sensitive Gj 
protein but not to Gs. Its properties were nearly identical to 
stably expressed rEP3ßR in CHO/rEP3pR cells (Fig. 3a). How-
ever, in these cells PTX was less effective and suppressed the 
PGE2-mediated inhibition of forskolin-stimulated cAMP for-
3.4. Influence of different receptor domains on receptor 
G-protein coupling 
Receptor domains involved in G-protein coupling have 
been analyzed in several R7G receptors. A unifying principle 
has not emerged yet due to sometimes rather contradictory 
results. 
3.4.1. Role of the second and third intracellular loops. Ex-
periments with chimeric receptors showed that the third in-
tracellular loop plays a critical role in G-protein coupling of 
many receptors [17-23]. This was the case for the uncoupled 
dopamine D3-receptor in which the substitution of the third 
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Fig. 4. Inhibition of forskolin-stimulated cAMP formation in CHO/ 
rEP3ßR and HepG2/rEP3hEP4R cells by PGE2 and M&B 28767 
cAMP formation in CHO/rEP3pR and HepG2/rEP3hEP4R cells was 
induced by 1 μΜ forskolin for 10 min at 37°C in the presence of 
the indicated concentrations of PGE2 or the EP3R agonists M&B 
28767. cAMP content in the cells was determined by radioimmu-
noassay. cAMP formation in the absence of PGE2 or M&B 28767 
was set equal to 100%. Values are means ± S.E. of 3 different experi-
ments performed in duplicate. 
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intracellular loop with that of the Gj-coupled dopamine D2-
receptor led to functional G; coupling, and for the Gq-coupled 
muscarinic Ml receptor, in which the substitution of this do-
main with the loop of the Gs-coupled ß-adrenergic receptor 
led to an additional Gs coupling [17,21]. Experiments in which 
only parts of this intracellular loop were exchanged showed 
that a dodecapeptide near the N-terminus of this domain 
could mediate Gs coupling [22]. However, the Gs-coupled ß-
adrenergic receptor substitutions in the second and third loops 
with sequences of the Gj-coupled a2-adrenergic receptor 
caused only decreased Gs but conferred no Gj coupling [22]. 
3.4.2. Role of the C-terminal domain. The normally Gs-
coupled ß-adrenergic receptor with parts of the third intracel-
lular loop and the C-terminal domain of the G;-coupled 0C2-
adrenergic receptor showed an additional coupling to G; [22]. 
Additional coupling to G; and Gq was also observed after 
truncation of the main portion of the C-terminal domain of 
the Gs-coupled PTH receptor [24]. A direct participation of 
the C-terminal domain in determining G-protein specificity 
and G-protein activation could be shown for the EP3R. 
Four splice variants of the bovine EP3R, which differed 
only in their C-terminal sequence, coupled to different G-pro-
teins [9]. Two of these isoforms coupled to Gs protein, one to 
Gj and one to Gj, Gs and Gq. The splice variant which 
coupled to all three G-proteins was also found for the mouse 
EP3R and showed similar promiscuous G-protein coupling 
[25]. However, seven C-terminal splice variants of the human 
EP3R [26] which are in part highly homologous to the se-
quence of the bovine EP3R C-terminal domains were all ex-
clusively coupled to Gi protein. This discrepancy in G-protein 
coupling specificity could be due to the high expression level 
of the bovine EP3R variants in a heterologous expression 
system or due to species specific sequence differences. 
In the current study the C-terminal domain of the Gs-
coupled I1EP4R was not able to shift the Gj-coupled rEP3ßR 
to a Gs-coupled receptor or to confer an additional Gs cou-
pling. In contrast, the chimeric rEP3hEP4R not only retained 
its rEP3ßR binding profile but also its Gj coupling properties. 
Thus, the hEP4R C-terminal domain seemed not to contain 
sufficient information for coupling the receptor to the Gs pro-
tein. This is in contrast to the different coupling profiles of the 
bovine EP3R splice variants but in line with the coupling 
properties of the human EP3R splice variants. 
3.5. Influence of the C-terminal domain on G-protein activity 
When the C-terminal domain of the mouse EP3R was trun-
cated directly after the EP3R splice junction which was com-
mon for all splice variants and shortened the C-terminal do-
main to 10 amino acids (Fig. 1), the receptor no longer 
showed agonist-induced G; activation but was constitutively 
active [27,28]. Apparently, the C-terminal domain had the role 
of keeping the Gj protein inactive as long as the receptor had 
not bound an agonist. 
In the present study the C-terminal domain of the hEP4R 
was able to take over this role of the rEP3ßR C-terminal 
domain to prevent the hybrid rEP3hEP4R from being consti-
tutively active. A reason for this behavior could be the pres-
ence of negative regulatory elements located in both the 
rEP3ßR and hEP4R C-terminal domain, which keep the 
rEP3ßR and the rEP3hEP4R in an inactive conformation 
and prevent ligand-independent Gj protein activation. This 
is surprising because the rEP3ßR and hEP4R C-terminal do-
mains are totally different in size and share no significant 
sequence homology. Potential candidates which can modulate 
protein coupling and activation are post-translational modifi-
cations like phosphorylation [29]. It is possible that the rE-
P3ßR and hEP4R C-terminal domains show a similar modifi-
cation pattern, because both C-terminal domains contain 
potential phosphorylation sites which can possibly arrest the 
receptor/Gj protein complex in an inactive state in the absence 
of a ligand. 
In summary, the C-terminal domain of the EP3ßR does not 
seem to be the critical intracellular domain conferring G-pro-
tein coupling specificity; rather it appears to confer agonist-
dependent coupling control: it may function as a negative 
regulator involved in the maintenance of a nonsignalling state 
of the ligand-free receptor. This effect can be mimicked by 
substitution with the C-terminal domain of the hEP4R. 
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